169 related articles for article (PubMed ID: 36540259)
41. Harnessing
Keinänen O; Fung K; Brennan JM; Zia N; Harris M; van Dam E; Biggin C; Hedt A; Stoner J; Donnelly PS; Lewis JS; Zeglis BM
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28316-28327. PubMed ID: 33106429
[TBL] [Abstract][Full Text] [Related]
42. Clip to Click: Controlling Inverse Electron-Demand Diels-Alder Reactions with Macrocyclic Tetrazines.
Novianti I; Kowada T; Mizukami S
Org Lett; 2022 May; 24(17):3223-3226. PubMed ID: 35446571
[TBL] [Abstract][Full Text] [Related]
43. Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter,
Shalgunov V; Engudar G; Bohrmann L; Wharton L; Maskell K; Johann K; Barz M; Schaffer P; Herth MM; Radchenko V
Nucl Med Biol; 2022; 104-105():11-21. PubMed ID: 34839209
[TBL] [Abstract][Full Text] [Related]
44. Development of
García-Vázquez R; Jørgensen JT; Bratteby KE; Shalgunov V; Hvass L; Herth MM; Kjær A; Battisti UM
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215356
[TBL] [Abstract][Full Text] [Related]
45. Pretargeted PET Imaging Using a Bioorthogonal
Billaud EMF; Belderbos S; Cleeren F; Maes W; Van de Wouwer M; Koole M; Verbruggen A; Himmelreich U; Geukens N; Bormans G
Bioconjug Chem; 2017 Dec; 28(12):2915-2920. PubMed ID: 29191024
[TBL] [Abstract][Full Text] [Related]
46. Pretargeted Imaging beyond the Blood-Brain Barrier-Utopia or Feasible?
Lopes van den Broek S; Shalgunov V; García Vázquez R; Beschorner N; Bidesi NSR; Nedergaard M; Knudsen GM; Sehlin D; Syvänen S; Herth MM
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297303
[TBL] [Abstract][Full Text] [Related]
47. Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine.
Hapuarachchige S; Artemov D
Front Oncol; 2020; 10():1131. PubMed ID: 32793481
[TBL] [Abstract][Full Text] [Related]
48. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
[TBL] [Abstract][Full Text] [Related]
49. Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging.
Reiner T; Lewis JS; Zeglis BM
J Vis Exp; 2015 Feb; (96):e52335. PubMed ID: 25742199
[TBL] [Abstract][Full Text] [Related]
50. Side-by-Side Comparison of Five Chelators for
Damerow H; Hübner R; Judmann B; Schirrmacher R; Wängler B; Fricker G; Wängler C
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944969
[TBL] [Abstract][Full Text] [Related]
51.
Stéen EJL; Jørgensen JT; Johann K; Nørregaard K; Sohr B; Svatunek D; Birke A; Shalgunov V; Edem PE; Rossin R; Seidl C; Schmid F; Robillard MS; Kristensen JL; Mikula H; Barz M; Kjær A; Herth MM
ACS Nano; 2020 Jan; 14(1):568-584. PubMed ID: 31820928
[TBL] [Abstract][Full Text] [Related]
52. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
[TBL] [Abstract][Full Text] [Related]
53. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.
Cook BE; Adumeau P; Membreno R; Carnazza KE; Brand C; Reiner T; Agnew BJ; Lewis JS; Zeglis BM
Bioconjug Chem; 2016 Aug; 27(8):1789-95. PubMed ID: 27356886
[TBL] [Abstract][Full Text] [Related]
54. Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers.
Meyer JP; Tully KM; Jackson J; Dilling TR; Reiner T; Lewis JS
Bioconjug Chem; 2018 Feb; 29(2):538-545. PubMed ID: 29378403
[TBL] [Abstract][Full Text] [Related]
55. Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211.
Timperanza C; Jensen H; Bäck T; Lindegren S; Aneheim E
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111352
[TBL] [Abstract][Full Text] [Related]
56. Chemical trigger-enabled bioconjugation reaction.
Xie F; Jia X; Zhu Z; Wu Y; Jiang H; Yang H; Cao Y; Zhu R; Zhou B; Du J; Tang Y
Org Biomol Chem; 2021 Oct; 19(38):8343-8351. PubMed ID: 34518846
[TBL] [Abstract][Full Text] [Related]
57. An Extended Approach for the Development of Fluorogenic trans-Cyclooctene-Tetrazine Cycloadditions.
Siegl SJ; Galeta J; Dzijak R; Vázquez A; Del Río-Villanueva M; Dračínský M; Vrabel M
Chembiochem; 2019 Apr; 20(7):886-890. PubMed ID: 30561884
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of Organo [
Otaru S; Imlimthan S; Sarparanta M; Helariutta K; Wähälä K; Airaksinen AJ
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156020
[TBL] [Abstract][Full Text] [Related]
59.
Spampinato A; Kužmová E; Pohl R; Sýkorová V; Vrábel M; Kraus T; Hocek M
Bioconjug Chem; 2023 Mar; 34(4):772-80. PubMed ID: 36972479
[TBL] [Abstract][Full Text] [Related]
60. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
